Şunu aradınız:: baseline (İspanyolca - Almanca)

baseline
baseline

change from baseline
1 ,5 1,12

línea de base (baseline)
basislinie (baseline)

atributos del tipo de objeto espacial baseline
attribute der objektart baseline

points to consider on adjustment for baseline covariates
points to consider on adjustment for baseline covariates

roles de asociación del tipo de objeto espacial baseline
assoziationsrollen der objektart baseline

esta estimación recibe el nombre de lifecycle baseline 2.
diese schätzung läuft unter der bezeichnung „lifecycle baseline 2“.

55 | reservada | juridical recorder baseline requirements | |
55 | gereserveerd | juridical recorder baseline requirements | |

información y archivo sobre el taller anual de baseline: anuncio de manifestación.
information und veranstaltung.

etsi ts 103 172 (marzo de 2012)-electronic signatures and infrastructures (esi); pades baseline profile.
etsi ts 103 172 (märz 2012) — electronic signatures and infrastructures (esi); pades baseline profile.

los días 15 y 16 de diciembre de 1998 se celebrará en paderborn, alemania, un seminario en materia de validación de usuarios y el cuarto taller sobre baseline.
ein anwenderüberprüfungsseminar und der vierte baseline­workshop finden am 15. und 16. dezember 1998 in paderborn, deutschland, statt.

usar & lt;directoriogt; como referencia en lugar de & lt;directorio_basegt;/baseline
& lt;ordnergt; anstelle von & lt;basis_ordnergt;/output als referenz verwenden

concept paper on the development of a cpmp points to consider on biostatistical/methodological issues arising from cpmp discussions on licensing applications: adjustment for baseline covariates adoptada en febrero de 2000
note for guidance on non-clinical local tolerance testing of medicinal products zur stellungnahme freigegeben im september 2000

d baseline y para mejorar la fertilidad), pero los climático ef _ in it io no f me a sur c h y of o b j ec cambios de otro tipo requerirán fre­cuentemente apoyo oficial, como es el
d baseline ef _ in it io n of m e as u r für „beide seiten” sein, d. h. sowohl für erforderlich c h sein, um die emissionen y of ob je c

fuente: observations until 1995, eurostat baseline scenario for the period 1996­2015 (observaciones hasta 1995, hipótesis demográfica basica de eurostat para el período 1996­2015).
quelle: beobachtungen; für 1996-2015: eurostat-basisszenario.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: